Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease

BACKGROUND: Recognizing clinical manifestations heralding the development of Alzheimer’s disease (AD)-related cognitive impairment could improve the identification of individuals at higher risk of AD who may benefit from potential prevention strategies targeting preclinical population. We aim to cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Grau-Rivera, Oriol, Navalpotro-Gomez, Irene, Sánchez-Benavides, Gonzalo, Suárez-Calvet, Marc, Milà-Alomà, Marta, Arenaza-Urquijo, Eider M., Salvadó, Gemma, Sala-Vila, Aleix, Shekari, Mahnaz, González-de-Echávarri, José Maria, Minguillón, Carolina, Niñerola-Baizán, Aida, Perissinotti, Andrés, Simon, Maryline, Kollmorgen, Gwendlyn, Zetterberg, Henrik, Blennow, Kaj, Gispert, Juan Domingo, Molinuevo, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890889/
https://www.ncbi.nlm.nih.gov/pubmed/33597012
http://dx.doi.org/10.1186/s13195-021-00781-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890889/
https://www.ncbi.nlm.nih.gov/pubmed/33597012
http://dx.doi.org/10.1186/s13195-021-00781-z

Ejemplares similares